The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with ...

GSK (NYSE:GSK) has received Chinese regulatory approval for its drug Nucala, also known as mepolizumab, for the treatment of ...

GlaxoSmithKline ( (GSK) ) has provided an update. GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with ...

GSK (GSK) announced that the China National Medical Products Administration has approved Nucala, a monoclonal antibody that ...

China’s National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody from UK ...

London: GSK plc has announced that the China National Medical Products Administration has approved Nucala (mepolizumab), a ...

GSK announced on Friday that its monoclonal antibody ‘Nucala’, or mepolizumab, has received approval from China's National ...

GSK’s Nucala was approved in the US for severe asthma with an eosinophilic phenotype treatment. Credit: MAXSHOT.PL / Shutterstock. The China National Medical Products Administration (NMPA) has ...

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...

GSK's Nucala (mepolizumab) approved in China for treatment of adults with chronic rhinosinusitis with nasal polyps · Mepolizumab is the only anti-interleukin-5 approved in China for the ...

all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter GSK announced that its monoclonal antibody, Nucala (mepolizumab ...

GSK (NYSE:GSK) has announced the approval of its drug Nucala (mepolizumab) by the China National Medical Products Administration for treating adult patients with chronic rhinosinusitis with nasal ...